Jeffrey Gindi, MD
Hospitalist · Wilkes Barre, PANPI 1699898858
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Pfizer at 44.2% of the total. Reporting peaked in 2024 at $3,899 and has fallen 51.3% since, to $1,900 in 2025. Among hospitalist clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 47 payments — averaging $269.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$6K
- Teva Pharmaceuticals USA, Inc.$2K
- Ferring Pharmaceuticals Inc.$2K
- AstraZeneca$1K
- UCB, Inc.$375
- MDD US Operations, LLC$321
- plus $1K from 15 others
What the payments were for
- Consulting fees$5,42043%
- Speaking & faculty fees$3,66029%
- Travel & lodging$9678%
- Food & beverage$2,63321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 13 | $5,605 |
| Teva Pharmaceuticals USA, Inc. | 1 | $1,885 |
| Ferring Pharmaceuticals Inc. | 1 | $1,830 |
| AstraZeneca | 4 | $1,326 |
| UCB, Inc. | 3 | $375 |
| MDD US Operations, LLC | 3 | $321 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $250 |
| Gilead | 1 | $125 |
| Mylan Specialty L.p. | 1 | $125 |
| Acorda Therapeutics, Inc | 1 | $122 |
| Travere Therapeutics, Inc. | 1 | $114 |
| Novartis | 1 | $99 |
| Kyowa Kirin, Inc. | 1 | $92 |
| Organogenesis Inc. | 1 | $82 |
| E.r. Squibb & Sons, L.L.C. | 1 | $82 |
| Lilly USA, LLC | 3 | $77 |
| Johnson & Johnson | 5 | $71 |
| Intra-sana Laboratories | 1 | $50 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Melinta Therapeutics, LLC | 1 | $11 |
| AbbVie | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,680 in reported general payments places this provider in the 95th percentile of 1,287 hospitalist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 11 | $121 |
| Losartan Potassium | 13 | $80 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Wilkes Barre
- Katelyn YoungWilkes Barre$3K
- Ketul PatelWilkes Barre$3K
- Khalid AhmedPhiladelphia$55K
- Umang PatelLanghorne$21K
- Irfan AhsanPhiladelphia$21K
- Kevin VolppPhiladelphia$17K
- Amanulla KhajiWynnewood$15K
- Maria DrosouWynnewood$15K
- Joseph SabolPittsburgh$12K
- Ezekiel AdewaleMedia$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.